Akoya Biosciences (AKYA) Projected to Post Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA – Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect Akoya Biosciences to post earnings of ($0.22) per share and revenue of $18.10 million for the quarter.

Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.03). The business had revenue of $16.64 million during the quarter, compared to analysts’ expectations of $20.19 million. Akoya Biosciences had a negative net margin of 59.44% and a negative return on equity of 487.85%. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Stock Performance

NASDAQ:AKYA opened at $1.29 on Friday. The firm has a market capitalization of $64.44 million, a PE ratio of -1.33 and a beta of 1.36. The business’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.56. The company has a debt-to-equity ratio of 10.12, a current ratio of 0.61 and a quick ratio of 0.40. Akoya Biosciences has a 12 month low of $0.93 and a 12 month high of $3.42.

Wall Street Analysts Forecast Growth

AKYA has been the topic of several recent analyst reports. Canaccord Genuity Group dropped their target price on Akoya Biosciences from $1.80 to $1.08 and set a “hold” rating on the stock in a report on Monday, May 19th. Piper Sandler dropped their target price on Akoya Biosciences from $2.40 to $1.65 and set a “neutral” rating on the stock in a report on Monday, April 14th. Seven analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.51.

Check Out Our Latest Stock Analysis on AKYA

Hedge Funds Weigh In On Akoya Biosciences

Several hedge funds have recently made changes to their positions in AKYA. Bank of America Corp DE grew its holdings in shares of Akoya Biosciences by 39.6% during the fourth quarter. Bank of America Corp DE now owns 29,092 shares of the company’s stock worth $67,000 after purchasing an additional 8,258 shares during the last quarter. Invesco Ltd. purchased a new position in shares of Akoya Biosciences during the first quarter worth about $63,000. AQR Capital Management LLC grew its holdings in shares of Akoya Biosciences by 128.5% during the first quarter. AQR Capital Management LLC now owns 25,257 shares of the company’s stock worth $35,000 after purchasing an additional 14,203 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Akoya Biosciences by 24.3% during the first quarter. Goldman Sachs Group Inc. now owns 99,780 shares of the company’s stock worth $139,000 after purchasing an additional 19,475 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Akoya Biosciences by 131.7% during the first quarter. Rhumbline Advisers now owns 74,255 shares of the company’s stock worth $103,000 after purchasing an additional 42,204 shares during the last quarter. Hedge funds and other institutional investors own 79.42% of the company’s stock.

About Akoya Biosciences

(Get Free Report)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.